Pfizer (NYSE:PFE) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Pfizer (NYSE:PFE) in a research note issued to investors on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $45.00 target price on the biopharmaceutical company’s stock.

PFE has been the topic of several other reports. UBS Group upped their price target on Pfizer from $30.00 to $31.00 and gave the company a neutral rating in a research report on Wednesday, July 31st. Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an equal weight rating in a report on Wednesday, July 31st. StockNews.com raised shares of Pfizer from a hold rating to a buy rating in a report on Thursday, August 1st. Wells Fargo & Company upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an equal weight rating in a report on Wednesday, July 31st. Finally, Daiwa America raised Pfizer from a moderate buy rating to a strong-buy rating in a research note on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of Moderate Buy and an average target price of $34.54.

Pfizer Stock Down 0.3 %

PFE opened at $29.67 on Monday. Pfizer has a 12 month low of $25.20 and a 12 month high of $34.11. The company has a market cap of $168.13 billion, a PE ratio of -494.42, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company has a 50 day moving average of $29.35 and a 200 day moving average of $28.20.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period last year, the company earned $0.67 earnings per share. On average, sell-side analysts expect that Pfizer will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.66%. The ex-dividend date was Friday, July 26th. Pfizer’s payout ratio is currently -2,799.53%.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently added to or reduced their stakes in the business. Verity & Verity LLC grew its stake in shares of Pfizer by 11.8% during the second quarter. Verity & Verity LLC now owns 531,036 shares of the biopharmaceutical company’s stock valued at $14,858,000 after buying an additional 56,071 shares during the last quarter. Newbridge Financial Services Group Inc. grew its position in Pfizer by 21.1% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 18,462 shares of the biopharmaceutical company’s stock worth $517,000 after acquiring an additional 3,223 shares during the last quarter. Bluefin Capital Management LLC increased its stake in Pfizer by 9.0% in the 2nd quarter. Bluefin Capital Management LLC now owns 10,569 shares of the biopharmaceutical company’s stock worth $296,000 after purchasing an additional 869 shares during the period. Heritage Wealth Management Inc. bought a new stake in Pfizer in the second quarter valued at approximately $1,351,000. Finally, Lazari Capital Management Inc. boosted its stake in shares of Pfizer by 2.9% during the second quarter. Lazari Capital Management Inc. now owns 18,895 shares of the biopharmaceutical company’s stock valued at $529,000 after purchasing an additional 536 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.